ClinicalTrials.gg
CompletedNCT01792518Updated Mar 6, 2017Results posted

MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

A Phase 3 interventional study of Placebo and Linagliptin 5mg in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 74 sites in 12 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-03-06.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies testing linagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Linagliptin · Diabetes Mellitus, Type 2.

Enrollment
17th of 67
360 · median 175
Started
2013
with 6 others
Phase 3
31 of 67
none open now
Registered
32nd of 67
by date
Lead sponsor
36 of 67
Boehringer Ingelheim

Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, this one is the 17th largest by enrollment, is one of 7 that started in 2013, is one of 31 in phase 3, and was the 32nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 67 studies testing linagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About linagliptin

Linagliptin: first FDA approval 2011 (TRADJENTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing linagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Evaluate linagliptin in terms of glycemic control as defined by HbA1c after 24 weeks of treatment and in terms of renal efficacy as defined by changes in albuminuria (UACR) after 24 weeks of treatment.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of type 2 diabetes mellitus
  • Glycosylated () between 6.5 and 10% (inclusive)
  • Current therapy with ACEi or ARB at stable dose for 10 weeks
  • Urinary albumin-to-creatinine ratio (UACR): 30-3000 mg/g creatinine documented in the previous 12 months or detected at Screening.
  • Estimated (eGFR) greater than 30 ml/min.
  • Age between 18 and 80 years.

Exclusion criteria

Exclusion criteria:

  • Dual or triple blockade of the Renin Angiotensin System (RAS)
  • Uncontrolled hyperglycaemia
  • Mean arterial blood pressure > 110 mmHg
  • Known or allergy to the product, or their (including matching placebos).
  • Treatment with a glitazone within 6 months prior to .
  • Treatment with a DiPeptidyl-Peptidase 4 (DPP-4) inhibitor, a Glucagon Like Peptide-1 (GLP-1) agonist, a Sodium/Glucose coTransporter 2 (SGLT2) inhibitor, a dopamine-agonist, a bile-acid sequestrant a short acting (prandial) insulin or premixed insulin within 10 weeks prior to informed consent.
  • Treatment with anti-obesity drugs 10 weeks prior to informed consent.
  • Alcohol or drug abuse within 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake in the opinion of the investigator.
  • Current treatment with systemic (glucocorticoids) at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent.
  • Participation in another trial with an investigational drug within 2 months prior to informed consent.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
360 participants (actual)

Study arms

  • Experimental
    linagliptin 5mg

    linagliptin 5 mg once daily

    Drug: Linagliptin 5mg

  • Placebo comparator
    placebo

    matching placebo for linagliptin dose once daily

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. HbA1c Change From Baseline After 24 Weeks Double-blind Randomized Treatment

    Change from baseline in Glycated haemoglobin (HbA1c) \[%\] after 24 weeks of treatment with double- blind trial medication. The term "baseline" refers to the last observation before the start of any randomised trial treatment. The number of participants analysed displays the number of participants with available data at the timepoint of interest.

    Time frame: Baseline and 24 weeks

Secondary outcomes

  1. The Time Weighted Average of Percentage Change From Baseline in UACR During the Course of 24 Weeks of Treatment

    The time weighted average of percentage change from baseline in UACR (mg/g creatinine) during the course of 24 weeks of treatment. The term "baseline" for UACR refers to the geometric mean of UACR values measured at Visits 2 and 3. The number of participants analysed displays the number of participants with available data at the timepoint of interest. The Least Squares Means are adjusted geometric means.

    Time frame: Baseline and 24 weeks

  2. The Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) After 24 Weeks of Treatment

    The change from baseline in estimated glomerular filtration rate (eGFR) as assessed by chronic kidney disease epidemiology collaboration (CKD-EPI) equation (cystatin C) after 24 weeks of treatment. The term "baseline" refers to the last observation before the start of any randomised trial treatment. The number of participants analysed displays the number of participants with available data at the timepoint of interest. This outcome measure is a secondary safety endpoint.

    Time frame: Baseline and 24 weeks

07

Results

Posted Mar 6, 2017

Participant flow

360 patients were randomised and treated (Placebo: 178 patients, Linagliptin: 182 patients.)

Participant flow — Overall Study
MilestonePlaceboLinagliptin 5 mg
Started178182
Completed170175
Not completed87
Withdrew: Adverse event34
Withdrew: Protocol violation01
Withdrew: Lost to follow-up31
Withdrew: Withdrawal by subject20
Withdrew: Other reason01

Outcome measures

PrimaryHbA1c Change From Baseline After 24 Weeks Double-blind Randomized Treatment

Change from baseline in Glycated haemoglobin (HbA1c) \[%\] after 24 weeks of treatment with double- blind trial medication. The term "baseline" refers to the last observation before the start of any randomised trial treatment. The number of participants analysed displays the number of participants with available data at the timepoint of interest.

Time frame:
Baseline and 24 weeks
Reported as:
Least squares mean · Percentage of HbA1c
HbA1c Change From Baseline After 24 Weeks Double-blind Randomized Treatment
Percentage of HbA1cPlaceboLinagliptin 5 mg
HbA1c Change From Baseline After 24 Weeks Double-blind Randomized Treatment-0.03 ± 0.06-0.63 ± 0.06
Statistical analysis
  • Placebo vs Linagliptin 5 mg · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -0.60 · 95% CI -0.78 to -0.43Mean Difference (Final Values) is actually the Adjusted mean difference calculated as Linagliptin 5 mg minus Placebo.
SecondaryThe Time Weighted Average of Percentage Change From Baseline in UACR During the Course of 24 Weeks of Treatment

The time weighted average of percentage change from baseline in UACR (mg/g creatinine) during the course of 24 weeks of treatment. The term "baseline" for UACR refers to the geometric mean of UACR values measured at Visits 2 and 3. The number of participants analysed displays the number of participants with available data at the timepoint of interest. The Least Squares Means are adjusted geometric means.

Time frame:
Baseline and 24 weeks
Reported as:
Least squares mean · mg/g creatinine
The Time Weighted Average of Percentage Change From Baseline in UACR During the Course of 24 Weeks of Treatment
mg/g creatininePlaceboLinagliptin 5 mg
The Time Weighted Average of Percentage Change From Baseline in UACR During the Course of 24 Weeks of Treatment0.9487 ± 0.060.8902 ± 0.06
Statistical analysis
  • Placebo vs Linagliptin 5 mg · ANCOVA · p = 0.1954 · Ratio of adjusted geometric means: 0.94 · 95% CI 0.85 to 1.03Ratio of relative change for Linagliptin 5 mg over placebo is presented.
SecondaryThe Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) After 24 Weeks of Treatment

The change from baseline in estimated glomerular filtration rate (eGFR) as assessed by chronic kidney disease epidemiology collaboration (CKD-EPI) equation (cystatin C) after 24 weeks of treatment. The term "baseline" refers to the last observation before the start of any randomised trial treatment. The number of participants analysed displays the number of participants with available data at the timepoint of interest. This outcome measure is a secondary safety endpoint.

Time frame:
Baseline and 24 weeks
Reported as:
Least squares mean · milliliter/minute/1.73 square metre
The Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) After 24 Weeks of Treatment
milliliter/minute/1.73 square metrePlaceboLinagliptin 5 mg
The Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) After 24 Weeks of Treatment-2.35 ± 1.92-4.98 ± 1.89
Statistical analysis
  • Placebo vs Linagliptin 5 mg · Mixed Models Analysis · p = 0.3306 · Mean difference (final values): -2.63 · 95% CI -7.95 to 2.68Mean Difference (Final Values) is actually the Adjusted mean difference calculated as Linagliptin 5 mg minus Placebo.

Adverse events

Collected over From first drug administration until 28 days after the last drug administration, up to 240 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—8/178 (4.5%)27/178 (15.2%)
Linagliptin 5 mg—17/182 (9.3%)39/182 (21.4%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventPlaceboLinagliptin 5 mg
Cardiac failure congestiveCardiac disorders2/1780/182
Septic shockInfections and infestations2/1780/182
Vestibular disorderEar and labyrinth disorders0/1782/182
Sudden hearing lossEar and labyrinth disorders1/1780/182
PancreatitisGastrointestinal disorders1/1780/182
Pancreatitis acuteGastrointestinal disorders1/1781/182
PyrexiaGeneral disorders1/1780/182
Arteriovenous graft site infectionInfections and infestations1/1780/182
Kidney infectionInfections and infestations1/1780/182
PyelonephritisInfections and infestations1/1780/182
Most frequent other events
Most frequent other events
EventPlaceboLinagliptin 5 mg
HypoglycaemiaMetabolism and nutrition disorders10/17824/182
NasopharyngitisInfections and infestations10/17813/182
Upper respiratory tract infectionInfections and infestations9/1784/182

Baseline characteristics

Treated Set (TS) - including all patients treated with at least one dose of randomised trial medication.

Age, Continuous
Age, Continuous(Years)PlaceboLinagliptin 5 mgTotal
Mean60.1 ± 9.361.0 ± 10.060.6 ± 9.6
Gender
Gender(Participants)PlaceboLinagliptin 5 mgTotal
Female6566131
Male113116229
08

Study locations

74 sites
  • Boehringer Ingelheim Investigational Site
    Birmingham, Alabama, United States
  • Boehringer Ingelheim Investigational Site
    Long Beach, California, United States
  • Boehringer Ingelheim Investigational Site
    North Hollywood, California, United States
  • Boehringer Ingelheim Investigational Site
    Denver, Colorado, United States
  • Boehringer Ingelheim Investigational Site
    Miami, Florida, United States
  • Boehringer Ingelheim Investigational Site
    Evansville, Indiana, United States
  • Boehringer Ingelheim Investigational Site
    Flint, Michigan, United States
  • Boehringer Ingelheim Investigational Site
    Jackson, Mississippi, United States
  • Boehringer Ingelheim Investigational Site
    Asheboro, North Carolina, United States
  • Boehringer Ingelheim Investigational Site
    Charlotte, North Carolina, United States
  • Boehringer Ingelheim Investigational Site
    Fargo, North Dakota, United States
  • Boehringer Ingelheim Investigational Site
    Columbus, Ohio, United States
  • Boehringer Ingelheim Investigational Site
    Oklahoma City, Oklahoma, United States
  • Boehringer Ingelheim Investigational Site
    Knoxville, Tennessee, United States
  • Boehringer Ingelheim Investigational Site
    Houston, Texas, United States
  • Boehringer Ingelheim Investigational Site
    Edmonton, Alberta, Canada
  • Boehringer Ingelheim Investigational Site
    Victoria, British Columbia, Canada
  • Boehringer Ingelheim Investigational Site
    Mount Pearl, Newfoundland and Labrador, Canada
  • Boehringer Ingelheim Investigational Site
    London, Ontario, Canada
  • Boehringer Ingelheim Investigational Site
    Mississauga, Ontario, Canada
  • Boehringer Ingelheim Investigational Site
    Sarnia, Ontario, Canada
  • Boehringer Ingelheim Investigational Site
    Toronto, Ontario, Canada
  • Boehringer Ingelheim Investigational Site
    Waterloo, Ontario, Canada
  • Boehringer Ingelheim Investigational Site
    Gentofte, Denmark
  • Boehringer Ingelheim Investigational Site
    Hillerød, Denmark
  • Boehringer Ingelheim Investigational Site
    Silkeborg, Denmark
  • Boehringer Ingelheim Investigational Site
    Slagelse, Denmark
  • Boehringer Ingelheim Investigational Site
    Kerava, Finland
  • Boehringer Ingelheim Investigational Site
    Oulu, Finland
  • Boehringer Ingelheim Investigational Site
    Tampere, Finland
  • Boehringer Ingelheim Investigational Site
    Turku, Finland
  • Boehringer Ingelheim Investigational Site
    Bersée, France
  • Boehringer Ingelheim Investigational Site
    Bourg des Comptes, France
  • Boehringer Ingelheim Investigational Site
    Grenoble Cedex 09, France
  • Boehringer Ingelheim Investigational Site
    Le Creusot, France
  • Boehringer Ingelheim Investigational Site
    Marseille cedex, France
  • Boehringer Ingelheim Investigational Site
    Saint Mandé cedex, France
  • Boehringer Ingelheim Investigational Site
    Vieux Condé, France
  • Boehringer Ingelheim Investigational Site
    Vénissieux Cedex, France
  • Boehringer Ingelheim Investigational Site
    Aschaffenburg, Germany
  • Boehringer Ingelheim Investigational Site
    Asslar, Germany
  • Boehringer Ingelheim Investigational Site
    Dresden, Germany
  • Boehringer Ingelheim Investigational Site
    Düsseldorf, Germany
  • Boehringer Ingelheim Investigational Site
    Flörsheim, Germany
  • Boehringer Ingelheim Investigational Site
    Pirna, Germany
  • Boehringer Ingelheim Investigational Site
    Schweinfurt, Germany
  • Boehringer Ingelheim Investigational Site
    Aoba-ku,Sendai,Miyagi, Japan
  • Boehringer Ingelheim Investigational Site
    Chiyoda-ku,Tokyo, Japan
  • Boehringer Ingelheim Investigational Site
    Cyuo-ku,Tokyo, Japan
  • Boehringer Ingelheim Investigational Site
    Kita-ku, Osaka, Osaka, Japan
  • Boehringer Ingelheim Investigational Site
    Shimizu-ku,Shizuoka city,Shizuoka, Japan
  • Boehringer Ingelheim Investigational Site
    Suita,Osaka, Japan
  • Boehringer Ingelheim Investigational Site
    Teine-ku,Sapporo,Hokkaido, Japan
  • Boehringer Ingelheim Investigational Site
    Goyang, Korea, Republic of
  • Boehringer Ingelheim Investigational Site
    Jinju, Korea, Republic of
  • Boehringer Ingelheim Investigational Site
    Seongnam, Korea, Republic of
  • Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • Boehringer Ingelheim Investigational Site
    Wonju, Korea, Republic of
  • Boehringer Ingelheim Investigational Site
    Cebu City, Philippines, Philippines
  • Boehringer Ingelheim Investigational Site
    Pasig City, Philippines, Philippines
  • Boehringer Ingelheim Investigational Site
    San Juan City, Philippines, Philippines
  • Boehringer Ingelheim Investigational Site
    L'Hospitalet de Llobregat, Spain
  • Boehringer Ingelheim Investigational Site
    Madrid, Spain
  • Boehringer Ingelheim Investigational Site
    Pozuelo de Alarcon, Spain
  • Boehringer Ingelheim Investigational Site
    San Sebastian de los Reyes, Spain
  • Boehringer Ingelheim Investigational Site
    Valencia, Spain
  • Boehringer Ingelheim Investigational Site
    Changhua, Taiwan
  • Boehringer Ingelheim Investigational Site
    Kaohsiung, Taiwan
  • Boehringer Ingelheim Investigational Site
    New Taipei, Taiwan
  • Boehringer Ingelheim Investigational Site
    Taichung, Taiwan
  • Boehringer Ingelheim Investigational Site
    Tainan, Taiwan
  • Boehringer Ingelheim Investigational Site
    Taipei, Taiwan
  • Boehringer Ingelheim Investigational Site
    Hanoi, Vietnam, Vietnam
  • Boehringer Ingelheim Investigational Site
    Ho Chi Minh City, Vietnam
09

References and documents

Publications

  • Siwy J, Klein T, Rosler M, von Eynatten M. Urinary Proteomics as a Tool to Identify Kidney Responders to Dipeptidyl Peptidase-4 Inhibition: A Hypothesis-Generating Analysis from the MARLINA-T2D Trial. Proteomics Clin Appl. 2019 Mar;13(2):e1800144. doi: 10.1002/prca.201800144. Epub 2019 Jan 28. PubMed 30632692 ↗
  • Groop PH, Cooper ME, Perkovic V, Hocher B, Kanasaki K, Haneda M, Schernthaner G, Sharma K, Stanton RC, Toto R, Cescutti J, Gordat M, Meinicke T, Koitka-Weber A, Thiemann S, von Eynatten M. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. Diabetes Obes Metab. 2017 Nov;19(11):1610-1619. doi: 10.1111/dom.13041. Epub 2017 Jul 31. PubMed 28636754 ↗
  • Groop PH, Cooper ME, Perkovic V, Sharma K, Schernthaner G, Haneda M, Hocher B, Gordat M, Cescutti J, Woerle HJ, von Eynatten M. Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D trial. Diab Vasc Dis Res. 2015 Nov;12(6):455-62. doi: 10.1177/1479164115579002. Epub 2015 Jul 28. PubMed 26224765 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2013, a primary completion of Nov 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2013
First posted
Feb 15, 2013
Start
Feb 2013
Primary completionActual
Nov 2015
CompletionActual
Dec 2015
Results first posted
Mar 6, 2017
Last update
Mar 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01792518
Responsible party
Sponsor
First posted
Feb 15, 2013
Start date
Feb 2013
Primary completion
Nov 2015
Completion
Dec 2015
Results posted
Mar 6, 2017
Last update
Mar 6, 2017

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linagliptin

Start the discussion